# A Study of 2 Doses of MAP0010 in Asthmatic Children

> **NCT00697697** · PHASE3 · TERMINATED · sponsor: **Allergan** · enrollment: 192 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** 0.135mg MAP0010
- **DRUG:** 0.25mg MAP0010

## Key facts

- **NCT ID:** NCT00697697
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2009-08
- **Final completion:** 2009-12
- **Target enrollment:** 192 (ACTUAL)
- **Why stopped:** Corporate decision
- **Last updated:** 2014-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697697, "A Study of 2 Doses of MAP0010 in Asthmatic Children". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00697697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*